NewAmsterdam Pharma Company N.V. (NAMS) vs Recursion Pharmaceuticals, Inc. (RXRX)
A side-by-side comparison of NewAmsterdam Pharma Company N.V. and Recursion Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NAMS
NewAmsterdam Pharma Company N.V.
$22.04HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
RXRX
Recursion Pharmaceuticals, Inc.
$4.59HealthcareDelayed quote: Oct 6, 2026, 12:55 PM EDT
Total return — NAMS vs RXRX
growth of $100 · dividends reinvested · last 5yNAMS +129.1% (+18.0%/yr)RXRX -73.4% (-23.3%/yr)NAMS compounded faster over this window
Log scale — wide-divergence pair
NAMS RXRX
NAMS vs RXRX: by the numbers
- •NAMS is the larger company ($2.58B vs $2.41B market cap).
- •Both run net losses; RXRX's is the smaller (-945.92% vs -3644.21% net margin).
Metrics side by side
Valuation
| Metric | NAMS | RXRX |
|---|---|---|
| P/S ratio | 361.85 | 43.87 |
| P/B ratio | 4.08 | 2.63 |
Profitability
| Metric | NAMS | RXRX |
|---|---|---|
| Gross margin | 92.15% | -61.96% |
| Operating margin | -1002.90% | -867.87% |
| Net margin | -3644.21% | -945.92% |
| ROE | -41.10% | -56.71% |
| ROIC | -38.70% | -49.78% |
Growth (annualized)
| Metric | NAMS | RXRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 45.50% |
| Total return CAGR (5Y) | 18.30% | -25.86% |
Frequently asked
- How have NAMS and RXRX total returns compared?
- Over the past 5 years, NAMS delivered 18.30% and RXRX delivered -25.86% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
NewAmsterdam Pharma ROERecursion Pharmaceuticals ROENewAmsterdam Pharma operating marginRecursion Pharmaceuticals operating marginNewAmsterdam Pharma revenue growthRecursion Pharmaceuticals revenue growthNewAmsterdam Pharma free cash flowRecursion Pharmaceuticals free cash flow
NewAmsterdam Pharma & Recursion Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.